The MS market in the US is highly fragmented and is quite sticky, so I highly doubt that BG-12 will be able to garner a 50% market share during the next 3-5 years. Copaxone is currently the US market leader with a 40% TRx share (#msg-75407417); Avonex, Rebif, Betaseron, Gilenya, and Tysabri make up the other 60%.
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”